1. In Vivo
  2. >>Global Vision

A Rare Second Chance at Partnering Success for Vernalis' Underperforming Frova

 
• By Chris Morrison

Vernalis has bought back rights to its Frova migraine treatment in North America from Elan, agreeing to pay $55 million over the next two years. Frova, sold there by Elan and UCB, had failed to reach even the most modest sales expectations. Now Vernalis plans to re-partner the drug, hoping a label-extension to menstrual-associated migraine lands it significantly better terms than its original 1998 deal with Elan. But Vernalis needs to raise money to complete the buyout, and the dynamics of the US migraine market suggest that until it can differentiate the drug on the basis of the MAM label, a huge primary care sales force would be necessary to gain a respectable share of the market.

When Pfizer Inc. launched the seventh triptan migraine therapy into the US market in February 2003 it did so with a bang. The Big Pharma rolled out eletriptan (Relpax) under the considerable steam of 6,000 sales reps, aiming to take a bite out of market-dominating sumatriptan (Imitrex) from GlaxoSmithKline PLC . Barely noticed was the flagging progress of the sixth entrant, frovatriptan (Frova), launched in late 2002 and sold by Elan Corp. PLC , which focused on neurologists, and UCB Pharma Inc., the US affiliate of Belgian conglomerate UCB Group SA, which details primary care physicians (PCPs).

While Elan had managed to capture a respectable 7% market share among neurologists, these doctors write only 1% of total...

More from Global Vision

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.